Mergers and alliances in pharmaceuticals: Effects on innovation and R&D productivity

The Economics of Corporate Governance and Mergers

Volumn , Issue , 2008, Pages 262-287

  Grabowski, Henry ^a   Kyle, Margaret ^b  

^a DUKE UNIVERSITY   (United States)

^b LONDON BUSINESS SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 73949095529     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (47)

1. Akerlof,G.A. (1970), 'The market for "lemons": quality uncertainty and the market mechanism', Quarterly Journal of Economics, 84, 488-500.
2. Andrade, G., M. Mitchell and E. Stafford (2001), 'New evidence and perspectives on mergers', Journal of Economic Perspectives, 15(2), 103-20.
3. Arora, Ashish, Andrea Fosfuri and Alfonso Gambardella (2001), Markets for Technology: The Economics of Innovation and Corporate Strategy, Cambridge, MA: MIT Press.
4. Arora, Ashish, Alfonso Gambardella, Laura Magazzini and Fabio Pammolli (2007), 'A breath of fresh air? Firm types, scale, scope and selection effects in drug development', unpublished paper (available from the authors).
5. Arrow, Kenneth J. (1983), 'Innovation in large and small firms', in J. Ronen (ed.), Entrepreneurship, Lexington, MA: Lexington Books.
6. Burns,Lawton R., Sean Nicholson and John Evans (2005), 'Mergers, acquisitions and the advantages of scale in the pharmaceutical industry', in Lawton R. Burns (ed.), The Business of Healthcare, Cambridge: Cambridge University Press, pp. 223-70.
7. Carlton, Dennis W. (1995), 'Antitrust policy towards mergers when firms innovate: should antitrust recognize the doctrine of innovation markets?', testimony before the Federal Trade Commission on Headings on Global and Innovation Based Competition, 24 October.
8. Carrier, Michael J. (2008), 'Two puzzles resolved: of the Schumpeter-Arrow stalemate and pharmaceutical innovation markets', Iowa Law Review, 93(2), 393-450, available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_ id 977603.
9. CenterWatch (2000), 'Troubling numbers for big pharma consolidation', reported in In Vivo, July/August, pp. 2-3.
10. Clark, Iain (2001), 'Drug discovery - Resolving the bottlenecks', Horizons, pharmaceutical issue 1, December.
11. Cockburn, Iain (2006), 'Is the pharmaceutical industry in a productivity crisis?', in Adam Jaffe, Joshua Lerner and Scott Stern (eds), Innovation Policy and the Economy, vol. 7, Cambridge, MA: MIT Press, pp. 1-32.
12. Cockburn, Iain and Rebecca Henderson (2001), 'Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research', Journal of Health Economics, 20(6), 1033-57.
13. Danzon, Patricia, Andrew Epstein and Sean Nicholson (2007), 'Mergers and acquisitions in the pharmaceutical and biotech industries', Managerial and Decision Economics, 28(4/5), 307-28.
14. Danzon, Patricia, Sean Nicholson and Nuno Sousa Pereira (2005), 'Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances', Journal of Health Economics, 24(2), 317-39.
15. DiMasi, Joseph and Henry Grabowski (2007), 'The economics of new oncology drug development', Journal of Clinical Oncology, 25(2), 209-16.
16. DiMasi, Joseph and Cherie Pacquette (2004), 'The economics of follow-on drug research and development: trends in entry rates and the timing of development', PharmcoEconomics, 22, suppl. 2, 1-14.
17. DiMasi, Joseph, Ronald Hansen and Henry Grabowski (2003), 'The price of innovation: new estimates of drug development costs', Journal of Health Economics, 22, 141-85.
18. DiMasi, Joseph, Ronald Hansen, Henry Grabowski and Louis Lasagna (1991), 'The cost of innovation in the pharmaceutical industry', Journal of Health Economics, 10, 107-42.
19. Dorey, Emma (2001), 'GlaxoSmithKline present a biotech façade', Nature Biotechnology, 19(4), 294-5.
20. Ernst & Young Online (2007), 'Beyond borders: global biotechnology report 2007'; available at www.ey.com/beyondborders.
21. Gilbert, Richard J. and Steven C. Sunshine (1995), 'Incorporating dynamic efficiency concerns in merger analysis: the use of innovation markets', Antitrust Law Journal, 63, 569-602.
22. Gort, Michael (1969), 'An economic disturbance theory of mergers', Quarterly Journal of Economics, 83, 624-42.
23. Grabowski, Henry (2007), 'Competition between generic and branded drugs', in Frank A. Sloan and Chee-Ruey Hsieh (eds), Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective, Cambridge: Cambridge University Press, pp. 153-73.
24. Grabowski, Henry, John Vernon and Joseph DiMasi (2002), 'Returns on research and development for 1990s new drug introductions', PharmacoEconomics, 20, suppl. 3, 11-29.
25. Guedj, Ilan and David Scharfstein (2004), 'Organizational scope and investment: evidence from the drug development strategies and performance of biopharmaceutical firms', NBER Working Paper 10933, Cambridge, MA.
26. Haspeslagh, Philippe and David Jemison (1991), Managing Acquisitions: Creating Value through Corporate Renewal, New York: Free Press.
27. Henderson, Rebecca and Iain Cockburn (1996), 'Scale, scope, and spillovers: determinants of research productivity in the pharmaceutical industry', RAND Journal of Economics, 27(1), 32-59.
28. Higgins, Matthew. J. and Daniel Rodriguez (2006), 'The outsourcing of R&D through acquisition in the pharmaceutical industry', Journal of Financial Economics, 80, 351-83.
29. Hitt, Michael, R. Duane Ireland and Jeffrey Harrison (2001), 'Mergers and acquisitions: a value creating or value destroying strategy?', in Michael A.
30. Hitt, R. Edward Freeman and Jeffrey S. Harrison (eds), The Blackwell Handbook of Strategic Management, Malden, MA: Blackwell Business, pp. 384-408.
31. Koenig, Michael and Elizabeth Mezick (2004), 'Impact of mergers and acquisitions on research productivity within the pharmaceutical industry', Scientometrics, 59(1), 157-69.
32. Larsson, Rikard and Sydney Finkelstein (1999), 'Integrating strategic, organizational, and human resource perspectives on mergers and acquisitions: a case survey of synergy realization', Organization Science, 10(1), 1-26.
33. Mathieu, Mark (ed.) (2007), Parexel's Bio/Pharmaceutical R&D Scoreboard 2007/2008, Waltham, MA: Parexel International Corporation, pp. 77-87.
34. Morgan, Eleanor J. (2001), 'Innovation and merger decisions in the pharmaceutical industry', Review of Industrial Organization, 19, 181-97.
35. Mueller, Dennis C. (1986), The Modern Corporation: Profits, Power, Growth and Performance, Brighton, UK: Wheatsheaf Books.
36. Mueller, Dennis C. (1996), 'Lessons from the United States' antitrust history', International Journal of Industrial Organization, 14, 415-45.
37. Ornaghi, Carmine (2006), 'Mergers and innovation: the case of the pharmaceutical industry', University of Southampton, Working Paper.
38. Pisano, Gary (1997), 'R&D performance, collaborative arrangements, and the market for know-how: a test of the "lemons" hypothesis in biotechnology', Harvard Business School, Cambridge, MA, mimeo.
39. Pammolli, Fabio and Massimo Riccaboni (2004), 'Technological competencies in networks of innovators', in J. Cantwell, A. Gambardella and O. Grandstrand (eds), The Economics and Management of Technological Diversification, London and New York: Routledge.
40. Powell,Walter, Kenneth Koput and Laurel Smith-Doerr (1996), 'Interorganizational collaboration and the locus of innovation: networks of learning in biotechnology', Administrative Science Quarterly, 41, 116-45.
41. Rapp, Richard T. (1995), 'The misapplication of the innovation market approach to merger analysis', Antitrust Law Journal, 64, 19-47.
42. Ravenscraft, David J. and William F. Long (2000), 'Paths to creating value in pharmaceutical mergers', in Steven N. Kaplan (ed.), Mergers and Productivity, Chicago: University of Chicago Press.
43. Recombinant Capital (2007), 'Analysts notebook - Value of biotech out-licensing deals with pharma and biotech', available at http://www.recap.com/ consulting.nsf/ContentWebPublish/46C030923BB918ED882572A4006A58C5? OpenDocument.
44. Scherer, F.M. (1999), New Perspectives on Economic Growth and Technological Innovation, Washington, DC: The Brookings Institution.
45. Smith, Kenneth and James Quella (1995), 'Seizing the moment to capture value in a strategic deal', Mergers and Acquisitions, 29(4), 25-30.
46. Teece, David J. (1998), 'Capturing value from knowledge assets: the new economy, markets for know-how and intangible assets', California Management Review, 40(3), 55-79.
47. US Food and Drug Administration, Center for Drug Evaluation and Research (1999), 'From test tube to patient: improving health through human drugs (special report)', US Government Printing Office, Washington, DC, September.